EPH Receptor A7 Protein (EPHA7)

N° du produit ABIN2746578

Détail du produit

Antigène: EPH Receptor A7 (EPHA7)

Type de proteíne: Recombinant

Origine: Humain, Rat, Souris

Source: Escherichia coli (E. coli)

Application: Western Blotting (WB), Positive Control (PC)

Fonction: Purified Protein in ready-to-use SDS sample buffer.

Attributs du produit: EphAR7 selective antibodies were generated against a peptide taken from the human protein. The EphAR7-selective antibodies are affinity purified on an immobilized antigen based affinity matrix, the isolated antibodies were then stabilized in antibody stabilization buffer for long-term storage. The EphAR7-selective antibodies are fully characterized for applications in western blotting and ELISA at the recommended dilutions. The Supplier provides EphA7 Western blot positive control samples in SDS-PAGE sample buffer.

Purification: Purified Protein

Information d'application

Indications d'application: Antibodies were tested in ELISA and western blotting applications at 1:500 dilution using ABIN1686566 samples. Antibody dilutions for these antibodies are for reference only, investigators are expected to determine the optimal conditions. Application of this antibody in other protocols has not yet tested.
WB: > 1:500
IMM & IP pull-down assays: n.d.
IHC: n.d.
Investigators using this antibody in protocols other than listed above can request a complimentary sample of this antibody. n.d. not necessarily means the antibody is not suitable for that application, it simply means we have not yet characterized the antibody for that application.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: For 5 applications, volume varies from 100-200 μL in reduced SDS-PAGE sample buffer.

Stock: -20 °C

Stockage commentaire: -20 °C for long term storage

Détail du antigène

Antigène: EPH Receptor A7 (EPHA7)

Autre désignation: Ephrin Receptor A7 (EPHA7 Produits)

Synonymes: fc51g03 Protein, wu:fc51g03 Protein, si:dkey-23k6.1 Protein, EHK3 Protein, HEK11 Protein, Cek11 Protein, Ebk Protein, Ehk3 Protein, Hek11 Protein, Mdk1 Protein, CEPHA7 Protein, EPH receptor A7 Protein, eph receptor A7 Protein, ephrin type-B receptor 1-B Protein, Eph receptor A7 Protein, EPHA7 Protein, epha7 Protein, LOC100166161 Protein, Epha7 Protein

Sujet: The Ephrin receptors represent the largest group of Receptor Tyrosine Kinases, comprising of 14 members and divided in two subclasses (class A & B ephrin ligands) based on their abilities to bind and activate each other, and on sequence conservation. Ephrin-A (EFNA) class is anchored to the membrane by a glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) classes are trans-membrane proteins. The Eph family of receptors are similarly divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrins interact with a variety of membrane receptors that respond to chemokines, neurotransmitters or growth factors. Eph receptors are involved in central nervous system function and development, and in the modulation of different types of nociception. Eph receptors and their ligands play important roles in the regulation of cancer cell migration and invasion and are key regulators of axon guidance. They function in a variety of signaling modes by transducing signals from the cell exterior to the interior through ligand-induced activation of their kinase domain. Ephrin A7, a member of the ephrin family, encodes a soluble splice variant that acts as an extrinsic tumor suppressor. The common deletion of chromosome 6q has identified the ephrin receptor A7 (EPHA7) as a tumor suppressor in lymphomas. EPHA7 is implicated in lung cancer and other tumors, because of a broader therapeutic potential for antibody-mediated delivery of this tumor suppressor for cancer therapy. EPHA7 interferes with another Eph-receptor and blocks oncogenic signals in lymphoma cells. Consistent with this drug-like activity, administration of the purified EPHA7 protein produces antitumor effects against xenografted human lymphomas. Fusing EPHA7 to the anti-CD20 antibody (rituximab) can directly target this tumor suppressor to lymphomas in vivo thus rendering EPHA7 as tumor suppressor with immediate therapeutic potential. EPH and EPH-related receptors are implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The gene for EphAR6 is present on chromosome 3q11.2.

Poids moléculaire: 120 kDa

NCBI Accession: NP_004431

UniProt: Q15375

Pathways: Signalisation RTK